Join us at #ESMO2026 for an oral presentation on 1L olomorasib plus chemoimmunotherapy in KRAS G12C-mutant NSCLC, from the SUNRAY-01 Safety Lead-in cohort trial. 2652RO | Oct. 25 | 9:19 - 09:24 | Barcelona Auditorium Hall 9 View program details: https://t.co/MxHaXY2Yo5 #LungCancer